Treatment of gynecomastia with 4-hydroxy tamoxifen

Details Treatment of gynecomastia with 4-hydroxy tamoxifen Treatment of gynecomastia with 4-hydroxy tamoxifen

2011-06-28

2011-06-28

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07968532

ABSTRACT:
The present invention provides methods for treating and preventing gynecomastia by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with gynecomastia, this reduces the effective estrogen-androgen ratio in the breast tissue, thereby reducing ductal proliferation, epithelial and stromal hyperplasia, and pain. In patients at risk for developing gynecomastia, 4-hydroxy tamoxifen's anti-estrogenic effect prevents tissue proliferation and its accompanying pain.

REFERENCES:
patent: 4919937 (1990-04-01), Mauvais-Jarvis et al.
patent: 4973755 (1990-11-01), Grafe et al.
patent: 5045553 (1991-09-01), Ueda et al.
patent: 5613958 (1997-03-01), Kochinke et al.
patent: 5720963 (1998-02-01), Smith
patent: 5820877 (1998-10-01), Yamaguchi et al.
patent: 5904930 (1999-05-01), Fischer et al.
patent: 5945109 (1999-08-01), Schmidt et al.
patent: 6013270 (2000-01-01), Hargraves et al.
patent: 6503894 (2003-01-01), Dudley et al.
patent: 6632841 (2003-10-01), Af Ursin et al.
patent: 7485623 (2009-02-01), Bua
patent: 7507769 (2009-03-01), Nestour
patent: 7704516 (2010-04-01), Drouin et al.
patent: 7767147 (2010-08-01), Adachi et al.
patent: 7786172 (2010-08-01), De Lignieres
patent: 2001/0041718 (2001-11-01), Thompson et al.
patent: 2002/0115676 (2002-08-01), MacLean
patent: 2003/0065017 (2003-04-01), HuaZhu et al.
patent: 2003/0087885 (2003-05-01), Masini-Eteve et al.
patent: 2003/0150876 (2003-08-01), Walters et al.
patent: 2003/0175329 (2003-09-01), Azarnoff et al.
patent: 2004/0009994 (2004-01-01), MacLean et al.
patent: 2004/0086552 (2004-05-01), Klokkers et al.
patent: 2004/0138314 (2004-07-01), Bua
patent: 2005/0031695 (2005-02-01), Rouanet et al.
patent: 2005/0032909 (2005-02-01), Lignieres et al.
patent: 2005/0208139 (2005-09-01), Hilt et al.
patent: 2005/0209340 (2005-09-01), Le Nestour
patent: 2006/0105041 (2006-05-01), Masini-Eteve
patent: 2009/0186944 (2009-07-01), Rouanet et al.
patent: 32 38 984 (1983-05-01), None
patent: 38 36 862 (1990-05-01), None
patent: 0 513 832 (1992-11-01), None
patent: 0 792 640 (1997-09-01), None
patent: 1 579 856 (2005-09-01), None
patent: 1 579 857 (2005-09-01), None
patent: WO-95/24187 (1995-09-01), None
patent: WO 97/36570 (1997-10-01), None
patent: WO 99/33451 (1999-07-01), None
patent: WO 01/43775 (2001-06-01), None
patent: WO 2004/110420 (2004-12-01), None
patent: WO-2004/110420 (2004-12-01), None
www.wrongdiagnosis,com/g/gynecomastia/book-diseases-3a.htm. 2000. 5 sheets.
Rohrich et al. Classification and management of gynecomastia: defining the role of ultrasound-assited liposuction. Plastic and Reconstruction Surgery, Feb. 2003, vol. 111, Issue 2, pp. 909-923.
Hashimoto et al. Breast Imaging—A Correlative Atlas. Thieme Medical Publishers, Inc., 2003. pp. 360-361.
J.D. Gagnon et al., “Pre-Estrogen Breast Irradiation for Patients with Carcinomia of the Prostate: a critical review”, Journal of Urology, vol. 121:182-184, (1979).
N. Giambiagi et al., “Immunological Differences Between the Estradiol-, Tamxifen- and 4-Hydroxy-Tamoxifen-Estrogen Receptor Complexes Detected by Two Monoclonal Antibodies”, J. Steroid Biochem. vol. 30, No. 1-6, pp. 213-217, 1988.
A.R. Glass, “Gynecomastia”, Endocrinology and Metabolism Clinics of North America: Clinical Andrology, vol. 23, No. 4, pp. 825-837 (1994).
U. Gruntmanis et al., “Treatment of Gynecomastia”, Current Opinion in Investigational Drugs, vol. 2, No. 5, pp. 643-649 (2001).
V. Craig Jordan et al., “Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance”, Breast Cancer Research and Treatment, 2, pp. 123-138.
George G.J.M. Kuiper et al., “Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β”, Endocrinology, vol. 138, No. 3, 1997, pp. 863-870.
Frédérique Kuttenn et al., “Médecine et Thérapeutique”, C.R. Acad. Sc. Paris Série III, No. 12, 1985, 300:457-462.
Carmen Lazala et al., “Pubertal Gynecomastia”, Journal of Pediatric Endocrinology & Metabolism, 15:553-560 (2002).
Catherine Malet et al., “Tamoxifen and Hydroxytamoxifen IsomersversusEstradiol Effects on Normal Human Breast Cells in Culture”, Cancer Research, vol. 48, No. 24, Dec. 15, 1988, pp. 7193-7199.
Ruchi Mathur et al., “Gynecomastia: Pathomechanisms and treatment strategies”, Horm. Res., 48:95-102 (1997).
Pierre Mauvais-Jarvis et al., “trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Adminstration to Human Breast”, Cancer Research, vol. 46, Mar. 1986, pp. 1521-1525.
Henri Pujol et al., “Phase 1 study of percutaneous 4-hydroxy-tamoxifen with analysis of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue”, Cancer Chemother. Pharmacol., 36:493-498 (1995).
Lawrence H. Block Ph.D., Epidermal and Transdermal Drug Delivery, Medicated Topicals, Chapter 44, pp. 836-857.
David W. Robertson et al., “Synthesis of theEandZIsomers of the Antiestrogen Tamoxifen and Its Metabolite, Hydroxytamoxifen, in Tritium-Labeled Form”, J. Org. Chem., 1982, vol. 47, No. 12, pp. 2387-2393.
David W. Robertson et al., “Tamoxifen Antiestrogens, A Comparison of the Activity, Pharmacokinetics, and Metabolic Activation of theCISandTransIsomers of Tamoxifen” Journal of Steroid Biochemistry, vol. 16, pp. 1-13, (1982).
Hironobu Sasano et al., “Aromatase and Steroid Receptors in Gynecomastia and Male Breast Carcinoma: An Immunohistochemical Study”, Journal of Clinical Endocrinoly and Metabolisms, vol. 81, No. 8, pp. 3063-3067 (1996).
Fabrice Sauvez et al., “Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats”, Carcinogenesis vol. 20, No. 5, pp. 843-850 1999.
B.S. Shoker et al., “Abnormal Regulation of the Oestrogen Receptor in Benign Breast Lesions”, J. Clin. Pathol., 53:778-783 (2000).
Ashini L. Wijayaratne et al., “Comparative Analyses of Mechanistic Differences Among Antiestrogens”, Endocrinology, vol. 140, No. 2, pp. 5828-5840.
Brisson, et al., “Tamoxifen and Mammographic Breast Densities”, Cancer Epidemiology, Biomarkers & Prevention, vol. 9, 911-915 (2000).
“High Breast Density a Risk Factor”, pp. 1-4, http://www.breastcancer.org/research—genetics—091902—pf.html (Aug. 11, 2005).
Lawrence N. Parker et al., “Treatment of Gynecomastia with Tamoxifen: A Double Blind Crossover Study”, Metabolism, vol. 35, No. 8 Aug. 1986, pp. 705-708.
Alberti et al.; “In Vivo Assesment of Enhanced Topical Delivery of Terbinafine to Human Stratum Corneum”; J. of Controlled Release; 71:319-327 (2001).
Bodian, Ph.D. et al.; “Prognostic Significance of Benign Proliferative Breast Disease;” Cancer, Jun. 15, 1993; vol. 71, No. 12, pp. 3896-3907.
Tan-Chiu, et al.; “Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer;” Journal of the National Cancer Institute; vol. 95, No. 4, Feb. 19, 2003, pp. 302-307.
Fentiman, I.S. et al., “Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial,” Br. J. Surg. 1988, vol. 75, September, 845-846.
Fentiman, I.S. et al., “Studies of tamoxifen in women with mastalgia,” The British Journal of Clinical Practice, Supplement 68, vol. 43, No. 11, Nov. 1989, pp. 34-36.
Fentiman, Ian S., “Tamoxifen and Mastalgia an Emerging Indication,” Drugs, vol. 32, No. 6, Dec. 1986, pp. 477-480.
Friend et al; “Simple Alkyl Esters as Skin Permeation Enhancers;” Journal of Controlled Release; 9(1):33-31 (Jun. 1989) (Abstract only).
IBIS Investigators; “First Results from the International Breast Cancer Intervention Study (IBIS-I): a Randomised Prevention Trial;” The L

Affiliated with

Also associated with

Rating

Treatment of gynecomastia with 4-hydroxy tamoxifen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of gynecomastia with 4-hydroxy tamoxifen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of gynecomastia with 4-hydroxy tamoxifen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2717252